AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Alpine Immune Sciences Announces Poster Presentation at 2020 Crohn’s & Colitis Congress

January 6, 2020 GMT

SEATTLE--(BUSINESS WIRE)--Jan 6, 2020--

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2020 Crohn’s & Colitis Congress taking place January 23-25, 2020, in Austin, Texas.

Details of the presentation are as follows:

An abstract of the presentation is available in the online planner section of the Crohn’s & Colitis Congress website and in the Congress Mobile App.

About ALPN-101

ALPN-101 is a novel Fc fusion protein of a human inducible T cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgD™), and a first-in-class therapeutic designed to inhibit simultaneously the CD28 and ICOS inflammation pathways. CD28 and ICOS are closely-related costimulatory molecules with partially overlapping roles in T cell activation likely playing a role in multiple autoimmune and inflammatory diseases. In preclinical models of graft versus host disease, inflammatory arthritis, connective tissue disease, and multiple sclerosis, ALPN-101 demonstrates efficacy superior to agents blocking the CD28 – CD80/86 or ICOS - ICOSL pathways alone.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics, creating potentially powerful multifunctional immunotherapies to improve patients’ lives via unique protein engineering technologies. Alpine has two lead programs. The first, ALPN-101 for autoimmune/inflammatory diseases, is a selective dual T cell costimulation blocker engineered to reduce pathogenic T and B cell immune responses by blocking ICOS and CD28. ALPN-101 has recently completed enrollment in a Phase 1 healthy volunteer trial. The second, ALPN-202 for cancer, is a conditional CD28 costimulator and dual checkpoint inhibitor. Alpine is backed by world-class research and development capabilities, a highly-productive scientific platform, and a proven management team. For more information, visit www.alpineimmunesciences.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200106005338/en/

CONTACT: Investor Relations:

Pure Communications

Courtney Dugan, 212-257-6723

cdugan@purecommunications.comMedia Relations:

Pure Communications

Sheryl Seapy, 213-262-9390

sseapy@w2ogroup.com

KEYWORD: UNITED STATES NORTH AMERICA WASHINGTON

INDUSTRY KEYWORD: BIOTECHNOLOGY SCIENCE HEALTH RESEARCH

SOURCE: Alpine Immune Sciences, Inc.

Copyright Business Wire 2020.

PUB: 01/06/2020 07:30 AM/DISC: 01/06/2020 07:30 AM

http://www.businesswire.com/news/home/20200106005338/en